A position from a non-expert mid-career health manager. 
Comments and mutual aid welcome. Opus/Gemini used for search, research synthesis and drafting - but these words are nearly all my own (sorry for you dear reader).

There is an Ebola outbreak unfolding now in eastern Democratic Republic of the Congo. As of 26 May 2026, DRC's health ministry reports 121 confirmed cases (17 deaths) and over 1,077 suspected cases (246 suspected deaths) across Ituri, North Kivu and South Kivu, with confirmed spread to Kampala, Uganda. The WHO has declared it a Public Health Emergency of International Concern and raised its national risk assessment to "very high." This is DRC's 17th recorded outbreak since 1976 — and it began barely five months after the last one ended.

This post argues something the EA community has said in the abstract since its earliest days: organising to fund and support early intervention in epidemics is among the most impactful things we can do.

However, EAs probably also say that ebola won’t scale widely, this already has significant funding (~$350m) and attention to control the disease, and the potential scale of its impact is nothing near the X-risks associated with engineered pathogens.

I'm offering a counter: its just so tractable that we can do a lot here to improve DALY style outcomes, and there are things we can do to learn how to respond better to potential disease-based x-risks too.

1. Ebola hurts

Ebola kills up to 40% of those infected with the Bundibugyo strain, and historically up to 90% for the Zaire strain. It kills fast and frighteningly, and the people most likely to be infected are those who did the most loving thing available to them: caring for a sick relative, or preparing a body for burial. Funeral rites that involve washing and touching the deceased — acts of dignity and devotion — are among the primary transmission vectors.

The harm radiates outward. Households lose breadwinners and caregivers. Survivors carry stigma and long-term sequelae. And the wider community suffers a second epidemic of disrupted ordinary healthcare: during the 2014–16 West African outbreak, the collapse of routine obstetric, malaria and TB services produced excess mortality rivalling Ebola's direct death toll. In the current outbreak, this lands on a population already enduring one of the world's most neglected humanitarian crises — nearly 10 million people across the affected provinces face acute hunger, amid active conflict.

This is suffering of a kind, scale and concentration that a relatively small, well-timed intervention can meaningfully reduce.

2. Funding early intervention is probably extremely cost-effective

The core economic fact about epidemics is that costs compound exponentially while response capacity scales linearly. Every week of delay multiplies the eventual caseload, the eventual death toll, and the eventual price of containment.

A peer-reviewed compartment-model study of Sierra Leone found that intervening just four weeks earlier would have averted roughly 10,000 cases and 8,800 deaths — about 456,000 DALYs. That implies a cost-per-DALY in early response that is plausibly competitive with GiveWell top charities, before even counting the averted macroeconomic damage. And that damage is the larger share: the World Bank's analysis of West Africa found that most economic loss came not from treating the sick but from "aversion behaviour" — healthy people withdrawing from markets, travel and work out of fear.

While there is a lot less certainty than non-emergency scenarios, early epidemic response is plausibly in the same tier as leading global health interventions, and the "go early, go hard" logic holds across multiple modelling approaches and disease types. 

3. Central Africa's outbreak is different

Three differences from West Africa 2014 or DRC 2018–20:

The virus is different — and there's no vaccine, and no treatment for Bundibugyo. Most DRC outbreaks have been Zaire ebolavirus, for which we have two licensed vaccines and a ring-vaccination strategy that worked in 2018–20. This outbreak is Bundibugyo, which has caused only three outbreaks ever (Uganda 2007, DRC 2012, now). LSHTM's vaccine centre calls this a "technology blind spot": commercial and research funding followed the common strain, leaving the rarer one neglected. This is one of the market failures EA biosecurity folk have pointed to — and which Open Philanthropy's Sherlock Biosciences bet and others tried to pre-empt.

Tough times in the DRC The epicentre is Ituri — a high-traffic mining region with intense cross-border population movement, embedded in active armed conflict (ADF, CODECO, M23). Insecurity directly degrades the response: it restricts the movement of surveillance and contact-tracing teams and limits humanitarian access — the precise conditions under which the Sierra Leone modelling showed that rapid, well-resourced scale-up becomes most life-saving.

Detection was slow, and underreporting is high. WHO received the first alert of an "unknown illness with high mortality" on 5 May; confirmation took ten more days, partly because standard rapid field tests are calibrated to Zaire/Sudan strains and can miss Bundibugyo. The gap between ~120 confirmed and ~1,000 suspected cases reflects diagnostic scarcity and likely substantial underreporting — echoing the verification challenges GiveWell-adjacent retrospectives documented in West Africa.

4. We know what activities to fund

The response toolkit is well-established, and with no vaccine available, the WHO has been explicit that strategy "will rely heavily on comprehensive public health measures." things like:

• Surveillance and rapid diagnostics find cases early. Every day shaved off detection prevents compounding harms. Testing is a gap.
• Contact tracing maps the transmission web; in a mobile, cross-border, conflict-affected setting this requires more resources.
• Safe and dignified burials address a leading transmission route. They were one of the most agile, scalable interventions in West Africa — burial-team capacity can be doubled in weeks.
• Infection prevention and control (IPC) plus supportive clinical care keep health workers alive (they are disproportionately infected) and, even without a specific treatment, supportive care saves lives (e.g. dehydration).
• Community engagement. The repeating lesson (e.g. WHO) — is that outbreaks are only controlled when communities are mobilised.
• Funding the vaccine/therapeutic trials. Because there's no licensed Bundibugyo product, we’re in a world of enabling the funding and enablement of emergency clinical trials of candidate vaccines and treatments. Africa CDC has committed to a Bundibugyo vaccine by end of 2026; the EU has put €7.4m into a WHO R&D blueprint to fast-track trials. Does this create the context for unusually effective vaccine research funding?

Isn’t our collective ability to deploy all of this relevant to a potential higher-mortality human engineered biorisk?

5. We have some critical information gaps, again…

I can tell you what works. I cannot yet tell you, with confidence, which specific organisation a marginal pound should go to right now for the best expected value, or where a marginal week of skilled volunteering or lobbying does most good. 

I’m embarrassed about this gap, given the movement’s focus on pandemic response as a priority over a decade ago. SoGive's 2020 survey of biorisk orgs found donor attention barely moved even after COVID; we keep re-learning the "panic-then-neglect" dynamic rather than building standing capacity.

Would you, dear reader, be interested in helping to bring together:

1. Donation routes. There are options for great orgs that tick boxes on safe and dignified burials e.g. IFRC and their local partners, and isolation units like MSF but who don’t have ebola / DRC specific funding routes I can find. There are local NGOs but no associated evaluation of their impact or efficacy. Then there is Alima who may or may not have trust and presence on the ground. Is one of the things we can do lobby for better donation routes in early epidemic responses - or create an active fund?
2. Lobbying activities. Pandemic response and preparedness advocacy - presumably we want a link between active epidemics and how they are responded to alongside pandemic preparedness and innovation such as https://cepi.net/ ‘s work? Is now the right time? Are there other EA groups, people or orgs engaged in this that want help?
3. Volunteering avenues. Especially for those of us with some relevant skills - where, how, how much impact?

Please do share your thoughts in the comments.

6. Are we big enough as a movement to build a response capability?

The EA case for pandemic preparedness as scalable, tractable and neglected is old and, I think, correct — Toby Ord's The Precipice puts engineered pandemics among the leading existential risks, and the biosecurity community has produced serious work on surveillance, next-gen PPE, and precision response. But most of it is upstream — prevention and detection. There is comparatively little organised response capacity that can mobilise people and money fast, at the right moment, in the right way.

• Is it time to build, or back, a standing rapid-response capability — a register of health-focused EAs, medics, biorisk professionals, logisticians, and "territorial-army"-style trained responders ready to support outbreaks like this when they hit?
• What already exists that does this well, so we don't reinvent it? EA Funds' biosecurity allocations, Coefficient Giving's GCR funds, and operational partners like MSF and CEPI all exist — but is there a coordinating layer that lets a willing, skilled community plug in during a live emergency?
• If there isn't, should a small group of us scope one? 

Conclusion / discussion

We have a live outbreak of a horrible disease with the potential to get much bigger.

We have a lot of uncertainty, but some pointers towards give-well level or better cost-effectiveness if we can interrupt transmissions earlier in the response or do at least as well as the overall NGO effort in the West African ebola epidemic on the margin, as Give Well stated in its blog:

“We estimate that the several billion dollar effort, taken as a whole, could easily have saved lives as cost-effectively as our top charities – something that we don’t believe is usually the case in a disaster”.

We don’t have a clear donation or support route.

The constraints faced by early outbreak responses - funding, insight, coordination - are things many EAs are plausibly well positioned to resolve.

This kind of situation will repeat itself.

There are probably things we can do if we organise ourselves for all outbreaks, using this one as a catalyst.